Adaptimmune Therapeutics annual debt-to-equity ratio
2018
2019
2020
2021
2022
2023
2024
Adaptimmune Therapeutics Debt-to-Equity Ratio Growth & History (ADAPY)
Adaptimmune Therapeutics's debt-to-equity ratio was 6.26 for fiscal 2024.
View full Adaptimmune Therapeutics company overviewAdaptimmune Therapeutics annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2024 | 2024-12-31 | 6.26 | 5.62 | +880.64% |
| 2023 | 2023-12-31 | 0.64 | 0.36 | +126.60% |
| 2022 | 2022-12-31 | 0.28 | 0.16 | +127.93% |
| 2021 | 2021-12-31 | 0.12 | 0.05 | +77.95% |
| 2020 | 2020-12-31 | 0.07 | −0.14 | −66.26% |
| 2019 | 2019-12-31 | 0.21 | 0.10 | +95.54% |
| 2018 | 2018-12-31 | 0.11 | — | — |
Adaptimmune Therapeutics quarterly debt-to-equity ratio
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q4 2024 | 2024-12-31 | 6.26 | 5.62 | +880.64% |
| Q3 2024 | 2024-09-30 | 0.93 | 0.64 | +220.60% |
| Q2 2024 | 2024-06-30 | 0.49 | 0.28 | +136.46% |
| Q1 2024 | 2024-03-31 | 0.97 | 0.70 | +257.05% |
| Q4 2023 | 2023-12-31 | 0.64 | 0.36 | +126.60% |
| Q3 2023 | 2023-09-30 | 0.29 | 0.09 | +46.98% |
| Q2 2023 | 2023-06-30 | 0.21 | 0.04 | +22.01% |
| Q1 2023 | 2023-03-31 | 0.27 | 0.11 | +71.11% |
| Q4 2022 | 2022-12-31 | 0.28 | 0.16 | +127.93% |
| Q3 2022 | 2022-09-30 | 0.20 | 0.09 | +83.39% |
| Q2 2022 | 2022-06-30 | 0.17 | 0.09 | +109.23% |
| Q1 2022 | 2022-03-31 | 0.16 | 0.09 | +116.27% |
| Q4 2021 | 2021-12-31 | 0.12 | 0.05 | +77.95% |
| Q3 2021 | 2021-09-30 | 0.11 | 0.04 | +71.01% |
| Q2 2021 | 2021-06-30 | 0.08 | 0.02 | +42.48% |
| Q1 2021 | 2021-03-31 | 0.07 | −0.06 | −43.96% |
| Q4 2020 | 2020-12-31 | 0.07 | −0.14 | −66.26% |
| Q3 2020 | 2020-09-30 | 0.06 | −0.11 | −62.67% |
| Q2 2020 | 2020-06-30 | 0.06 | −0.08 | −58.88% |
| Q1 2020 | 2020-03-31 | 0.13 | −0.00 | −0.57% |
| Q4 2019 | 2019-12-31 | 0.21 | 0.10 | +95.54% |
| Q3 2019 | 2019-09-30 | 0.17 | 0.08 | +86.51% |
| Q2 2019 | 2019-06-30 | 0.14 | −0.01 | −8.16% |
| Q1 2019 | 2019-03-31 | 0.13 | — | — |
| Q4 2018 | 2018-12-31 | 0.11 | — | — |
| Q3 2018 | 2018-09-30 | 0.09 | — | — |
| Q2 2018 | 2018-06-30 | 0.15 | — | — |
Adaptimmune Therapeutics debt-to-equity ratio trends
Over the last five fiscal years, Adaptimmune Therapeutics's debt-to-equity ratio increased from 0.21 to 6.26, a change of 6.06. The latest reported quarter, Q4 2024, shows 6.26.
About the metric
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
Calculation and source
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Adaptimmune Therapeutics source filings ↗